{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T21:54:07Z","timestamp":1763330047718,"version":"3.37.3"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"1159","license":[{"start":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T00:00:00Z","timestamp":1715385600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To compare the survival and objective response rate (ORR) of the patients receiving estimated tumour absorbed dose (ETAD) &amp;lt;140\u2009Gy versus ETAD \u2265140\u2009Gy in patients with advanced chemorefractory colorectal carcinoma liver metastases (CRCLM) treated with yttrium-90 transarterial radioembolization (90Y TARE).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Between August 2016 and August 2023 adult patients with unresectable, chemorefractory CRCLM treated with 90Y TARE using glass particles, were retrospectively enrolled. Primary outcomes were overall survival (OS) and hepatic progression free survival (hPFS). Secondary outcome was ORR.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 40 patients with a mean age of 66.2\u2009\u00b1\u20097.8\u2009years met the inclusion criteria. Mean ETAD for group 1 (ETAD &amp;lt;140\u2009Gy) and group 2 (ETAD \u2265140) were 131.2\u2009\u00b1\u200917.4\u2009Gy versus 195\u2009\u00b1\u200945.6\u2009Gy, respectively. The mean OS and hPFS for group 1 versus group 2 were 12\u2009\u00b1\u200910.3\u2009months and 8.1\u2009\u00b1\u20099.3\u2009months versus 9.3\u2009\u00b1\u20093\u2009months and 7.1\u2009\u00b1\u20098.4\u2009months, respectively and there were no significant differences (P\u2009=\u2009.181 and P\u2009=\u2009.366, respectively). ORR did not show significant difference between the groups (P\u2009=\u2009.432).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In real-world practice, no significant difference was found in OS, hPFS, and ORR between patients who received ETAD &amp;lt;140\u2009Gy versus ETAD \u2265140\u2009Gy in patients with CRCLM, in this series.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Advances in knowledge<\/jats:title>\n                  <jats:p>This study demonstrated that increased tumour absorbed doses in radioembolization may not provide additional significant advantage for OS and hPFS for patients with CRCLM.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjr\/tqae096","type":"journal-article","created":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T04:29:25Z","timestamp":1715401765000},"page":"1255-1260","source":"Crossref","is-referenced-by-count":1,"title":["Are survival outcomes dependent on the tumour dose threshold of 139 Gy in patients with chemorefractory metastatic colorectal cancer treated with yttrium-90 radioembolization using glass particles? A real-world single-centre study"],"prefix":"10.1093","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4008-3395","authenticated-orcid":false,"given":"Osman Melih","family":"Topcuoglu","sequence":"first","affiliation":[{"name":"Department of Radiology, Yeditepe University Hospitals , Kosuyolu 34718, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tolga","family":"Orhan","sequence":"additional","affiliation":[{"name":"Department of Radiology, Yeditepe University Hospitals , Kosuyolu 34718, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5620-2881","authenticated-orcid":false,"given":"Ay\u015fegul","family":"Gormez","sequence":"additional","affiliation":[{"name":"Department of Radiology, Yeditepe University Hospitals , Kosuyolu 34718, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0912-8214","authenticated-orcid":false,"given":"Nalan","family":"Alan","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Yeditepe University Hospitals , Kosuyolu 34718, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"issue":"11","key":"2024061918455206100_tqae096-B1","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1007\/s00270-022-03215-x","article-title":"Trans-arterial radioembolization dosimetry in 2022","volume":"45","author":"Garin","year":"2022","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"7","key":"2024061918455206100_tqae096-B2","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jvir.2023.03.011","article-title":"Evolution of personalized dosimetry for radioembolization of hepatocellular carcinoma","volume":"34","author":"Knight","year":"2023","journal-title":"J Vasc Interv Radiol"},{"issue":"2","key":"2024061918455206100_tqae096-B3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2967\/jnumed.111.094235","article-title":"Dosimetry based on 99mTc-macroaggregated albumin SPECT\/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results","volume":"53","author":"Garin","year":"2012","journal-title":"J Nucl Med"},{"issue":"7","key":"2024061918455206100_tqae096-B4","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s00259-013-2395-x","article-title":"Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept","volume":"40","author":"Garin","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"2024061918455206100_tqae096-B5","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.2967\/jnumed.120.255745","article-title":"Dose-response and dose-toxicity relationships for glass 90Y radioembolization in patients with liver metastases from colorectal cancer","volume":"62","author":"Alsultan","year":"2021","journal-title":"J Nucl Med"},{"issue":"1","key":"2024061918455206100_tqae096-B6","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13550-018-0419-z","article-title":"90Y-PET\/CT-based dosimetry after selective internal radiation therapy predicts outcome in patients with liver metastases from colorectal cancer","volume":"8","author":"Levillain","year":"2018","journal-title":"EJNMMI Res"},{"issue":"1","key":"2024061918455206100_tqae096-B7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13550-017-0292-1","article-title":"Clinical and imaging-based prognostic factors in radioembolisation of liver metastases from colorectal cancer: a retrospective exploratory analysis","volume":"7","author":"Willowson","year":"2017","journal-title":"EJNMMI Res"},{"issue":"3","key":"2024061918455206100_tqae096-B8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2967\/jnumed.114.145177","article-title":"Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis","volume":"56","author":"Garin","year":"2015","journal-title":"J Nucl Med"},{"issue":"1","key":"2024061918455206100_tqae096-B9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial","volume":"6","author":"Garin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"2024061918455206100_tqae096-B10","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1007\/s00259-020-05163-5","article-title":"International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres","volume":"48","author":"Levillain","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2024061918455206100_tqae096-B11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40658-021-00394-3","article-title":"EANM dosimetry committee series on standard operational procedures: a unified methodology for 99mTc-MAA pre- and 90Y peri-therapy dosimetry in liver radioembolization with 90Y microspheres","volume":"8","author":"Chiesa","year":"2021","journal-title":"EJNMMI Phys"},{"issue":"2","key":"2024061918455206100_tqae096-B12","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-022-05956-w","article-title":"Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group","volume":"50","author":"Salem","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"2024061918455206100_tqae096-B13","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s00259-019-04340-5","article-title":"Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group","volume":"46","author":"Salem","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"2024061918455206100_tqae096-B14","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1007\/s00259-022-05774-0","article-title":"A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study","volume":"49","author":"Lam","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2024061918455206100_tqae096-B15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00270-020-02642-y","article-title":"Clinical application of trans-arterial radioembolization in hepatic malignancies in europe: first results from the prospective multicentre observational study CIRSE registry for SIR-spheres therapy (CIRT)","volume":"44","author":"Helmberger","year":"2021","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"5","key":"2024061918455206100_tqae096-B16","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.2214\/AJR.20.25315","article-title":"Yttrium-90 hepatic radioembolization for advanced chemorefractory metastatic colorectal cancer: survival outcomes based on right- versus left-sided primary tumor location","volume":"217","author":"Wu","year":"2021","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"2024061918455206100_tqae096-B17","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000443644","article-title":"Right sided colon cancer as a distinct histopathological subtype with reduced prognosis","volume":"33","author":"Nitsche","year":"2016","journal-title":"Dig Surg"},{"issue":"4","key":"2024061918455206100_tqae096-B18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/jso.20156","article-title":"Two colons-two cancers: paradigm shift and clinical implications","volume":"88","author":"Gervaz","year":"2004","journal-title":"J Surg Oncol"},{"issue":"2","key":"2024061918455206100_tqae096-B19","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1159\/000491778","article-title":"Distinguishable prognostic signatures of left- and right-sided colon cancer: a study based on sequencing data","volume":"48","author":"Liang","year":"2018","journal-title":"Cell Physiol Biochem"},{"issue":"35","key":"2024061918455206100_tqae096-B20","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1200\/JCO.21.01839","article-title":"Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase III trial","volume":"39","author":"Mulcahy","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"2024061918455206100_tqae096-B21","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1200\/JCO.22.01690","article-title":"Treatment of metastatic colorectal cancer: ASCO guideline","volume":"41","author":"Morris","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"2024061918455206100_tqae096-B22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13550-019-0533-6","article-title":"Analysis of differences between 99mTc-MAA SPECT- and 90Y-microsphere PET-based dosimetry for hepatocellular carcinoma selective internal radiation therapy","volume":"9","author":"Kafrouni","year":"2019","journal-title":"EJNMMI Res"},{"issue":"1","key":"2024061918455206100_tqae096-B23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13550-023-01011-3","article-title":"Predictive value of 99mTc-MAA-based dosimetry in personalized 90Y-SIRT planning for liver malignancies","volume":"13","author":"Riveira-Martin","year":"2023","journal-title":"EJNMMI Res"},{"key":"2024061918455206100_tqae096-B24","article-title":"Focus on uniformity, not dose: the folly of yttrium-90 transarterial radioembolization dose-escalation studies","volume":"5","author":"Nuffer","year":"2024","journal-title":"J Vasc Interv Radiol"},{"key":"2024061918455206100_tqae096-B25","article-title":"Need for a practical dosimetry paradigm that incorporates dose heterogeneity","volume":"1","author":"Lam","year":"2024","journal-title":"J Vasc Interv Radiol"}],"container-title":["British Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjr\/advance-article-pdf\/doi\/10.1093\/bjr\/tqae096\/57824417\/tqae096.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/97\/1159\/1255\/58280352\/tqae096.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/97\/1159\/1255\/58280352\/tqae096.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T18:46:17Z","timestamp":1718822777000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjr\/article\/97\/1159\/1255\/7668439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":25,"journal-issue":{"issue":"1159","published-online":{"date-parts":[[2024,5,10]]},"published-print":{"date-parts":[[2024,6,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjr\/tqae096","relation":{},"ISSN":["0007-1285","1748-880X"],"issn-type":[{"type":"print","value":"0007-1285"},{"type":"electronic","value":"1748-880X"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,5,10]]}}}